What are the clinical consequences of the new MASLD nomenclature, and how does it change our understanding of steatotic liver disease?

The introduction of the new steatotic liver disease (SLD) nomenclature marks a significant shift in the field, replacing NAFLD with MASLD and introducing new disease categories such as MetALD. But what does this mean for clinicians, researchers, and patients?

In this webinar, Prof. Maja Thiele, an internationally recognized expert in steatotic liver disease, explores the evidence behind the new nomenclature and its implications for disease prevalence, prognosis, risk stratification, and clinical practice. Together with hosts Prof. Manuel Castro Cabezas and Prof. Christophe Moreno, she discusses emerging data on MASLD, MetALD, and alcohol-related liver disease and examines how metabolic dysfunction influences liver-related outcomes.

What you’ll learn
This session covers key topics including:

  • The rationale behind the transition from NAFLD to MASLD and the broader SLD nomenclature
  • Whether existing knowledge from the NAFLD era can be translated to MASLD
  • The prevalence and prognostic significance of MASLD, MetALD, and alcohol-related liver disease (ALD)
  • How metabolic dysfunction, including Type 2 Diabetes and insulin resistance, contributes to liver disease progression
  • The role of alcohol consumption in steatotic liver disease and the emergence of MetALD as a distinct category
  • Implications of the new nomenclature for non-invasive liver tests, screening strategies, and future research
  • Expert Q&A on diagnosis, risk factors, disease severity, and patient management

Speaker
Prof. Maja Thiele

Hosts
Prof. Manuel Castro Cabezas
Prof. Christophe Moreno